Barriers to utilizing long-acting injectable antipsychotic medications

Area of Science:

• Psychiatry
• Pharmacology
• Mental Health Treatment

Background:

• Long-acting injectable (LAI) antipsychotics offer superior relapse reduction compared to oral formulations.
• Schizophrenia treatment guidelines often prioritize oral antipsychotics, leading to underutilization of LAIs.
• A small percentage of eligible patients in the US receive LAI antipsychotic treatment.

Purpose of the Study:

• To identify and analyze the barriers encountered by psychiatrists in implementing the use of LAI antipsychotics.
• To understand the factors influencing the adoption of LAI antipsychotic medications in clinical practice.

Main Methods:

• An internet-based survey was administered to psychiatrists affiliated with Michigan State University.
• The survey collected data on practice characteristics, access to LAIs, psychiatrists' opinions, and perceived barriers.
• Thirty-six psychiatrists completed the survey, providing insights into LAI utilization.

Main Results:

• 83% of surveyed psychiatrists recognized patients who would benefit from LAIs, but only 61% had the capacity to administer them.
• Primary barriers included lack of ancillary support, personal preference for oral medications, and limited insurance coverage.
• Psychiatrists with the capability to administer LAIs were significantly more likely to utilize them (10 times more likely).

Conclusions:

• Psychiatrists in Michigan encounter substantial challenges in prescribing LAI antipsychotics.
• Addressing these barriers is crucial for improving schizophrenia patient outcomes through enhanced LAI utilization.
• Strategies to overcome these obstacles are discussed for potential implementation.